Caplin Point Laboratories Ltd.
NSE: CAPLIPOINT · Pharmaceuticals
Snapshot
Unlock Caplin Point Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Caplin Point Laboratories Limited is a pharmaceutical company that develops, manufactures, and markets a diverse range of generic formulations and branded products. Its extensive portfolio includes injectables, ophthalmic products, tablets, capsules, and various topical and liquid dosage forms.
Business Model
The company generates revenue through the production and export of pharmaceutical formulations, alongside the operation of its QueTenX e-commerce platform. It focuses on a broad spectrum of therapeutic segments, catering to both domestic and international markets.
- Incorporation Year:1990
Growth Outlook
Growth is driven by the expansion of its diverse product portfolio, including advanced dosage forms like lyophilized injections and inhalers. The company continues to leverage its manufacturing capabilities to penetrate emerging markets and strengthen its branded product presence.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to import bans or facility audits.
- Currency Volatility. As a significant exporter of pharmaceutical products, the company is exposed to fluctuations in foreign exchange rates that may impact profit margins.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector often leads to price erosion and margin compression for standard formulations.
- Supply Chain Disruptions. Dependence on the timely procurement of active pharmaceutical ingredients and raw materials makes the company vulnerable to global supply chain instability.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Caplin Point Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,187 Cr
TTM · consolidated
NET PROFIT
₹650 Cr
TTM · consolidated
EPS
₹84.36
TTM · consolidated
RETURN ON EQUITY
21.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
26.0%
TTM · consolidated
P/E
31.7x
Q4 FY26 · consolidated
EV/EBITDA
23.1x
Q4 FY26 · consolidated
EBITDA MARGIN
40.1%
TTM · consolidated
NET PROFIT MARGIN
28.8%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Caplin Point Laboratories Ltd.CAPLIPOINT | 12,103 | 31.67 | 23.06 | 12.9% | 40.1% | 21.4% | 26.0% | +28.5% |
Alembic Pharmaceuticals Ltd.APLLTD | 13,129 | 24.47 | 15.07 | 10.1% | 16.0% | 12.6% | 14.2% | -18.1% |
Rubicon ResearchRUBICON | 12,884 | — | — | — | 23.0% | — | — | — |
Alivus LifeALIVUS | 11,958 | 25.31 | 16.66 | 6.9% | 33.6% | 19.2% | 24.6% | +9.2% |
Cohance Lifesciences Ltd.COHANCE | 11,471 | 73.99 | 28.98 | 135.3% | 20.8% | 8.7% | 9.7% | -58.5% |
Concord Biotech Ltd.CONCORDBIO | 10,890 | 54.32 | 33.52 | -12.1% | 39.8% | 13.9% | 18.0% | -26.8% |
As of Q4 FY26
Financials
Caplin Point Laboratories Ltd.
NSE: CAPLIPOINT · Pharmaceuticals
Snapshot
Unlock Caplin Point Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Caplin Point Laboratories Limited is a pharmaceutical company that develops, manufactures, and markets a diverse range of generic formulations and branded products. Its extensive portfolio includes injectables, ophthalmic products, tablets, capsules, and various topical and liquid dosage forms.
Business Model
The company generates revenue through the production and export of pharmaceutical formulations, alongside the operation of its QueTenX e-commerce platform. It focuses on a broad spectrum of therapeutic segments, catering to both domestic and international markets.
- Incorporation Year:1990
Growth Outlook
Growth is driven by the expansion of its diverse product portfolio, including advanced dosage forms like lyophilized injections and inhalers. The company continues to leverage its manufacturing capabilities to penetrate emerging markets and strengthen its branded product presence.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to import bans or facility audits.
- Currency Volatility. As a significant exporter of pharmaceutical products, the company is exposed to fluctuations in foreign exchange rates that may impact profit margins.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector often leads to price erosion and margin compression for standard formulations.
- Supply Chain Disruptions. Dependence on the timely procurement of active pharmaceutical ingredients and raw materials makes the company vulnerable to global supply chain instability.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Caplin Point Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,187 Cr
TTM · consolidated
NET PROFIT
₹650 Cr
TTM · consolidated
EPS
₹84.36
TTM · consolidated
RETURN ON EQUITY
21.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
26.0%
TTM · consolidated
P/E
31.7x
Q4 FY26 · consolidated
EV/EBITDA
23.1x
Q4 FY26 · consolidated
EBITDA MARGIN
40.1%
TTM · consolidated
NET PROFIT MARGIN
28.8%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26